The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children
Background. Urinary tract infections (UTIs) are common and important clinical problem in childhood, and extended-spectrum-beta-lactamase- (ESBL-) producing organisms are the leading cause of healthcare-related UTIs. In this study, we aimed to evaluate the clinical efficacy and safety of ertapenem th...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2015/595840 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850158849268383744 |
|---|---|
| author | Ayse Karaaslan Eda Kepenekli Kadayifci Serkan Atici Gulsen Akkoc Nurhayat Yakut Sevliya Öcal Demir Ahmet Soysal Mustafa Bakir |
| author_facet | Ayse Karaaslan Eda Kepenekli Kadayifci Serkan Atici Gulsen Akkoc Nurhayat Yakut Sevliya Öcal Demir Ahmet Soysal Mustafa Bakir |
| author_sort | Ayse Karaaslan |
| collection | DOAJ |
| description | Background. Urinary tract infections (UTIs) are common and important clinical problem in childhood, and extended-spectrum-beta-lactamase- (ESBL-) producing organisms are the leading cause of healthcare-related UTIs. In this study, we aimed to evaluate the clinical efficacy and safety of ertapenem therapy in children with complicated UTIs caused by ESBL-producing organisms. Methods. Seventy-seven children with complicated UTIs caused by ESBL-producing organisms were included in this retrospective study, and all had been treated with ertapenem between January 2013 and June 2014. Results. Sixty-one (79%) females and sixteen (21%) males with a mean ± standard deviation (SD) age of 76.6±52 months (range 3–204, median 72 months) were enrolled in this study. Escherichia coli (E. coli) (n=67; 87%) was the most common bacterial cause of the UTIs followed by Klebsiella pneumoniae (K. pneumoniae) (n=9; 11.7%) and Enterobacter cloacae (E. cloacae) (n=1; 1.3%). The mean duration of the ertapenem therapy was 8.9±1.6 days (range 4–11). No serious drug-related clinical or laboratory adverse effects were observed, and the ertapenem therapy was found to be safe and well tolerated in the children in our study. Conclusion. Ertapenem is a newer carbapenem with the advantage of once-daily dosing and is highly effective for treating UTIs caused by ESBL-producing microorganisms. |
| format | Article |
| id | doaj-art-617dd9ae5a344f1bbcf1e0bf41aa81dd |
| institution | OA Journals |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-617dd9ae5a344f1bbcf1e0bf41aa81dd2025-08-20T02:23:45ZengWileyInternational Journal of Nephrology2090-214X2090-21582015-01-01201510.1155/2015/595840595840The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in ChildrenAyse Karaaslan0Eda Kepenekli Kadayifci1Serkan Atici2Gulsen Akkoc3Nurhayat Yakut4Sevliya Öcal Demir5Ahmet Soysal6Mustafa Bakir7Department of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyDepartment of Pediatric Infectious Diseases, Marmara University School of Medicine, 34890 Istanbul, TurkeyBackground. Urinary tract infections (UTIs) are common and important clinical problem in childhood, and extended-spectrum-beta-lactamase- (ESBL-) producing organisms are the leading cause of healthcare-related UTIs. In this study, we aimed to evaluate the clinical efficacy and safety of ertapenem therapy in children with complicated UTIs caused by ESBL-producing organisms. Methods. Seventy-seven children with complicated UTIs caused by ESBL-producing organisms were included in this retrospective study, and all had been treated with ertapenem between January 2013 and June 2014. Results. Sixty-one (79%) females and sixteen (21%) males with a mean ± standard deviation (SD) age of 76.6±52 months (range 3–204, median 72 months) were enrolled in this study. Escherichia coli (E. coli) (n=67; 87%) was the most common bacterial cause of the UTIs followed by Klebsiella pneumoniae (K. pneumoniae) (n=9; 11.7%) and Enterobacter cloacae (E. cloacae) (n=1; 1.3%). The mean duration of the ertapenem therapy was 8.9±1.6 days (range 4–11). No serious drug-related clinical or laboratory adverse effects were observed, and the ertapenem therapy was found to be safe and well tolerated in the children in our study. Conclusion. Ertapenem is a newer carbapenem with the advantage of once-daily dosing and is highly effective for treating UTIs caused by ESBL-producing microorganisms.http://dx.doi.org/10.1155/2015/595840 |
| spellingShingle | Ayse Karaaslan Eda Kepenekli Kadayifci Serkan Atici Gulsen Akkoc Nurhayat Yakut Sevliya Öcal Demir Ahmet Soysal Mustafa Bakir The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children International Journal of Nephrology |
| title | The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children |
| title_full | The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children |
| title_fullStr | The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children |
| title_full_unstemmed | The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children |
| title_short | The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children |
| title_sort | clinical efficacy and safety of ertapenem for the treatment of complicated urinary tract infections caused by esbl producing bacteria in children |
| url | http://dx.doi.org/10.1155/2015/595840 |
| work_keys_str_mv | AT aysekaraaslan theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT edakepeneklikadayifci theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT serkanatici theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT gulsenakkoc theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT nurhayatyakut theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT sevliyaocaldemir theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT ahmetsoysal theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT mustafabakir theclinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT aysekaraaslan clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT edakepeneklikadayifci clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT serkanatici clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT gulsenakkoc clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT nurhayatyakut clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT sevliyaocaldemir clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT ahmetsoysal clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren AT mustafabakir clinicalefficacyandsafetyofertapenemforthetreatmentofcomplicatedurinarytractinfectionscausedbyesblproducingbacteriainchildren |